Jeffrey R Curtis1, Sindhu R Johnson2, Donald D Anthony3, Reuben J Arasaratnam4, Lindsey R Baden5, Anne R Bass6, Cassandra Calabrese7, Ellen M Gravallese5, Rafael Harpaz8, Rebecca E Sadun9, Amy S Turner10, Eleanor Anderson Williams11, Ted R Mikuls12. 1. University of Alabama at Birmingham. 2. Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada. 3. Louis Stokes Cleveland VA Medical Center, MetroHealth Medical Center, and Case Western Reserve University, Cleveland, Ohio. 4. VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas. 5. Brigham and Women's Hospital, Boston, Massachusetts. 6. Hospital for Special Surgery and Weill Cornell Medicine, New York, New York. 7. Cleveland Clinic, Cleveland, Ohio. 8. Harpaz Herman Consultants, Atlanta, Georgia. 9. Duke University, Durham, North Carolina. 10. American College of Rheumatology, Atlanta, Georgia. 11. The Permanente Medical Group, Union City, California. 12. University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha.
Abstract
OBJECTIVE: To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID-19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs). METHODS: A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID-19 vaccine efficacy and safety, as well as literature for other vaccines in RMD patients. Task force members rated their agreement with draft consensus statements on a 9-point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings. RESULTS: Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID-19 vaccines in RMD patients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination. CONCLUSION: These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID-19 vaccines and to facilitate implementation of vaccination strategies for RMD patients.
OBJECTIVE: To provide guidance to rheumatology providers on the use of coronavirus disease 2019 (COVID-19) vaccines for patients with rheumatic and musculoskeletal diseases (RMDs). METHODS: A task force was assembled that included 9 rheumatologists/immunologists, 2 infectious disease specialists, and 2 public health physicians. After agreeing on scoping questions, an evidence report was created that summarized the published literature and publicly available data regarding COVID-19 vaccine efficacy and safety, as well as literature for other vaccines in RMDpatients. Task force members rated their agreement with draft consensus statements on a 9-point numerical scoring system, using a modified Delphi process and the RAND/University of California Los Angeles Appropriateness Method, with refinement and iteration over 2 sessions. Consensus was determined based on the distribution of ratings. RESULTS: Despite a paucity of direct evidence, 74 draft guidance statements were developed by the task force and agreed upon with consensus to provide guidance for use of the COVID-19 vaccines in RMDpatients and to offer recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination. CONCLUSION: These guidance statements, made in the context of limited clinical data, are intended to provide direction to rheumatology health care providers on how to best use COVID-19 vaccines and to facilitate implementation of vaccination strategies for RMDpatients.
Authors: David Simon; Koray Tascilar; Filippo Fagni; Gerhard Krönke; Arnd Kleyer; Christine Meder; Raja Atreya; Moritz Leppkes; Andreas E Kremer; Andreas Ramming; Milena L Pachowsky; Florian Schuch; Monika Ronneberger; Stefan Kleinert; Axel J Hueber; Karin Manger; Bernhard Manger; Carola Berking; Michael Sticherling; Markus F Neurath; Georg Schett Journal: Ann Rheum Dis Date: 2021-05-06 Impact factor: 19.103
Authors: M T Gómez Lluch; B Proy Vega; M Cabero Becerra; A Rodríguez; A Escalera Zalvide; S A Sánchez Journal: Rev Esp Quimioter Date: 2022-03-10 Impact factor: 2.515
Authors: Nevin Hammam; Samar Tharwat; Rawhya R El Shereef; Ahmed M Elsaman; Noha M Khalil; Hanan M Fathi; Mohamed N Salem; Hanan M El-Saadany; Nermeen Samy; Amany S El-Bahnasawy; Yousra H Abdel-Fattah; Marwa A Amer; Emad ElShebini; Amira T El-Shanawany; Dina H El-Hammady; Rasha Abdel Noor; Marwa ElKhalifa; Faten Ismail; Rasha M Fawzy; Amany R El-Najjar; Zahraa I Selim; Nouran M Abaza; Ahmed R Radwan; Mervat IAbd Elazeem; Wael Abdel Mohsen; Abdel Hafeez Moshrif; Eman F Mohamed; Loay I Aglan; Soha Senara; Maha E Ibrahim; Iman Khalifa; Rasha El Owaidy; Noha El Fakharany; Reem Hamdy A Mohammed; Tamer A Gheita Journal: Rheumatol Int Date: 2021-07-09 Impact factor: 2.631